(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback